Literature DB >> 23290582

The surgical management of neuroendocrine tumour hepatic metastases.

S Pathak1, I Dash, M R Taylor, G J Poston.   

Abstract

Although rare in incidence, patients with neuroendocrine tumours (NET) live for many years and so have a high prevalence, and NETs frequently metastasise to the liver (NLM). Numerous treatment options have been implemented both for cure, and to implement disease control. Surgical treatment consists of curative resection, palliative cytoreductive resection and transplantation. Complete surgical resection is possible only in a subset of people with NLMs due to various factors. Ablative therapies may also be used, either as an adjunct to surgery or as a primary treatment. The purpose of the article is to summarise surgical treatment strategies in the management of patients with hepatic neuroendocrine metastases.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23290582     DOI: 10.1016/j.ejso.2012.12.001

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

Review 1.  Controlled low central venous pressure reduces blood loss and transfusion requirements in hepatectomy.

Authors:  Zhi Li; Yu-Ming Sun; Fei-Xiang Wu; Li-Qun Yang; Zhi-Jie Lu; Wei-Feng Yu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 2.  Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.

Authors:  Sayee Sundar Alagusundaramoorthy; Roberto Gedaly
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Authors:  Nancy Sharma; Boris G Naraev; Eric G Engelman; M Bridget Zimmerman; David L Bushnell; Thomas M OʼDorisio; M Sue OʼDorisio; Yusuf Menda; Jan Müller-Brand; James R Howe; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.